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LETTERS
Extensively 
Drug-Resistant 
Tuberculosis, 
Lesotho 
To the Editor: Reports of ex-
tensively drug-resistant tuberculosis 
(XDR TB) in the Republic of South 
Africa have generated concern in the 
medical and public health literature 
(1,2). Given that XDR TB is spread 
through the air, it is not surprising that 
cases have been reported in multiple 
countries throughout the world (3). We 
report a documented case of XDR TB 
in Lesotho. This case is closely tied 
to transnational work in South Africa, 
thus raising concern about the spread 
of this disease across highly porous 
borders and the need for international 
attention to migrant worker health.
Lesotho is a mountainous nation 
that is home to 2 million people and 
completely surrounded by South Afri-
ca. It has the third highest rate of HIV 
in the world; an estimated 24%–30% 
of the population is infected (4). Le-
sotho also has a high prevalence of 
TB with an estimated 695 cases per 
100,000 population (5). Ten percent 
of patients with smear-positive TB are 
estimated to have multidrug-resistant 
TB (6). The US Centers for Disease 
Control and Prevention is undertaking 
a national reporting registration sur-
vey in Lesotho.
In 2007, the Ministry of Health 
and Social Welfare began work-
ing with Partners In Health and the 
Foundation for Innovative and New 
Diagnostics, Geneva, Switzerland, 
to document and treat drug-resistant 
TB in Lesotho. Hundreds of cases of 
drug-resistant TB have been reported 
in the country, and the patient we de-
scribe in this letter was reported to 
have XDR TB.
The patient was a 44-year-old 
man who had been working in the gold 
mines in South Africa. He had a his-
tory of receiving multiple treatments 
for TB while he was working in one of 
the mines. His condition was declared 
a treatment failure in July 2007. The 
patient was discharged from medical 
care in South Africa with no follow-up 
plan or medical records and was told, 
per his report, to “return home.” He 
traveled by road and bus to Lesotho 
and easily crossed the border. He was 
originally seen at a public TB clinic in 
Lesotho but, given his reports of prior 
TB treatment, his sputum was sent for 
culture and drug susceptibility test-
ing. He was followed up at his home 
with a daily visit from a village health 
worker trained in the management of 
drug-resistant TB. When XDR TB 
was conﬁ  rmed (in vitro resistance to 
at least isoniazid, rifampin, a ﬂ  uo-
roquinolone, and an injectable agent 
[7]), he was admitted to the hospital 
for drug-resistant TB patients in Leso-
tho and placed in a negative-pressure, 
single isolation room. 
When the patient sought treat-
ment from our program in October 
2007, he exhibited severe wasting and 
dyspnea. An HIV test result was posi-
tive; his CD4 count was 36 cells/μL. 
First-line drug susceptibility testing 
(carried out by the Medical Research 
Council [MRC], Pretoria, South Af-
rica) showed resistance to isoniazid, 
rifampin, and pyrazinamide.  On the 
basis of these results, on October 26, 
2007, he was empirically prescribed a 
regimen of second-line drugs: capre-
omycin, para-aminosalicylic acid, 
cycloserine, ethionamide, and cipro-
ﬂ   oxacin. One month later, second-
line drug susceptibility testing, sent 
by the medical team in Lesotho (none 
was ever sent during his treatment in 
South Africa) but carried out at MRC, 
showed additional resistance to ami-
kacin (MIC 1.0 μg/mL), capreomycin 
(MIC 2.5 μg/mL), and oﬂ  oxacin (MIC 
1.0 μg/mL) but susceptibility to ethi-
onamide (5.0 μg/mL). The patient’s 
regimen was changed to kanamycin, 
moxiﬂ   oxacin, ethionamide, para-
aminosalicylic acid, and cycloserine. 
Unfortunately, he died of his disease in 
December 2007. His known contacts 
are being monitored closely for signs 
and symptoms of TB. Reports have 
been made to the mine in which he 
was working, the Ministry of Health 
of South Africa, and the Ministry of 
Health of Lesotho. As of the writing 
of this letter, the South African Min-
istry of Health has made no formal re-
sponse regarding this patient.
The report of this case of XDR 
TB in Lesotho raises many concerns. 
First, XDR TB was readily found 
(along with other forms of drug-resis-
tant TB) in this small country that al-
ready has high prevalence of HIV. The 
potential for spread in the community 
as well as in hospital settings is sub-
stantial. The link to working in South 
Africa is also a major factor. Given 
the patient’s prior treatment while em-
ployed by a mining company and the 
literature reporting XDR TB in South 
Africa (8), XDR TB likely developed 
while he was working in the mines, 
and he brought the disease back to 
his home in Lesotho. Because South 
African mines rely heavily on migrant 
labor from countries such as Lesotho, 
Swaziland, and Mozambique, trans-
national spread of drug-resistant TB, 
including XDR TB, is quite probable 
and calls for a concerted international 
approach and institutional collabora-
tion for management and control of 
this epidemic. Infection control in 
the mines needs to be addressed, and 
international efforts to communicate 
that migratory populations are at risk 
for XDR TB need to be a priority in 
controlling the spread of this disease.
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Inquilinus limosus 
and Cystic Fibrosis
To the Editor: Inquilinus limo-
sus, a new multidrug-resistant species, 
was reported in 1999 as an unidenti-
ﬁ  ed gram-negative bacterium in a lung 
transplant patient with cystic ﬁ  brosis 
(CF) (1). This species was later char-
acterized by the description of 7 new 
isolates of I. limosus and 1 isolate of 
Inquilinus sp. (2). Infections and colo-
nizations by I. limosus have been doc-
umented mainly in adolescent or adult 
patients with CF. To date, 8 clinical 
cases have been described in Germany 
(3,4), 1 case in the United States (1), 5 
cases in France (5), and 1 case in the 
United Kingdom (6) (Table). Only 1 
isolate of Inquilinus sp. has been re-
covered from blood samples of a pa-
tient without CF who had prosthetic 
valve endocarditis (7). 
Because this bacterium is not re-
corded in all commercial identiﬁ  cation 
system databases currently available, 
a longitudinal study for I. limosus 
detection with a new real-time PCR 
assay with a Taqman probe (Applied 
Biosystems, Foster City, CA, USA), 
that targets the 16S rRNA gene, has 
been developed and compared with 
the culture isolation. Primers il1d (5′-
TAATACGAAGGGGGCAAGCGT-
3′) and il1r (5′-CACCCTCTCTTGGA
TT CAAGC-3′) and probe ilProbe 
(6FAM-GGTTCGTTGCGTCAGAT
GTGAAAG-TAMRA), which were 
used in this study, were designed on 
the basis of multisequence alignment 
of all I. limosus 16S rDNA sequences 
available in the GenBank database. 
To conﬁ  rm speciﬁ  city, the prim-
ers and probe were checked by using 
the BLAST program (www.ncbi.nlm.
nih.gov/blast/Blast.cgi) and also by 
using suspension of several bacteria 
recovered habitually in patients with 
CF. For sensitivity of the Taqman PCR 
assay (Applied Biosystems), the mini-
mal CFU detectable was 2 CFU/PCR. 
From January 2006 through June 
2007, 365 sputum samples recovered 
from 84 children and 61 adults with 
CF and 71 sputum samples recovered 
from 54 patients without CF were 
screened blindly for I. limosus. By us-
ing our real-time PCR, we detected 9 
I. limosus-positive samples from 4 pa-
tients with CF (Table); 8 of these sam-
ples were also culture positive. How-
ever, all sputum samples from patients 
without CF were negative. In 1 patient 
(Table, case 17), I. limosus was detect-
ed by using real-time PCR 3 months 
before the culture was positive. Ret-
rospectively, the patient’s medical ﬁ  le 
was rechecked and his clinical respira-
tory condition worsened brieﬂ  y at that 
stage, which indicates an infection 
by this bacterium. Thus, in our study, 
the incidence of I. limosus was 2.8% 
(4.9% for adults with CF and 1.2% 
for children with CF). The incidence 
of Burkholderia cepacia complex dur-
ing the same period and in the same 
patients was 2.1% (3 adults with CF 
were positive, data not shown).
The genus Inquilinus belongs 
to the α-Proteobacteria; the genus 
Azospirillum is the most closely re-
lated bacteria (2). This cluster of bac-
teria contains several strains that are 
able to grow under saline conditions 
and in bioﬁ  lms (8,9). The mucoid phe-
notype of I. limosus may contribute to 
its colonization and resistance to many 
antimicrobial drugs. Recently, the ex-
opolysaccharides (EPS) produced by I. 
limosus were studied. The authors in-
dicated that I. limosus produces main-
ly 2 EPSs that exhibit the same charge 
per sugar residue present in alginate, 
the EPS produced by Pseudomonas 
aeruginosa in patients with CF. This 
similarity may be related to common 
features of the EPS produced by these 
2 opportunistic pathogens that are re-
lated to lung infections (10). Trans-
mission of I. limosus between patients 
with CF is not known, but in the report 
from Chiron et al., 1 of the 5 patients 
with I. limosus had a brother who had 
never been colonized with this bacte-
rium despite living in the same home 
(5). Schmoldt et al. reported that 3 
patients were treated in the same out-
patient CF clinic during overlapping 
time periods and each patient was in-
fected/colonized by an individual I. li-
mosus clone, which suggests that there 
was no transmission among these pa-
tients (4). This bacterium has been re-
covered mainly from sputum of ado-
lescents (mean age 17 ± 6.47 years, 
range 8–35), except in our study with 
a 2-year-old boy, which suggests that 
this emerging bacterium may be hos-
pital acquired, as recently suggested 
(7). Because this bacterium is multire-
sistant to several antimicrobial drugs, 
particularly colistin, which is widely 
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